Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 14, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

NCT01727622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
FDG-PET, ASL-MRI, Lumbar Puncture
Drug · Other · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 89 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 14, 2026, 2:26 PM EDT
Completed No phase listed Observational

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

NCT02778438
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Quintiles, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

NCT04491006
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

NCT05077826
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia

NCT05270408
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Active Transcranial direct current stimulation (STARStim 8), Sham Transcranial direct current stimulation (STARStim 8)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Montelukast Therapy on Alzheimer's Disease

NCT03991988
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Montelukast, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

CBD for Individuals at Risk for Alzheimer's Disease

NCT05822362
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

OTC Hearing Aid and MCI

NCT06112860
View directory record Official record
Conditions
Hearing Loss, Mild Cognitive Impairment, Alzheimer Disease and Related Dementias (ADRD)
Interventions
Over the counter hearing aid, Communication Strategies Information/Counseling
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • La Crosse, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
80
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 14, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

NCT06484244
View directory record Official record
Conditions
Alzheimers Disease, Mild Cognitive Impairment
Interventions
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 2:26 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Software Validation Study-Cognitive Status Indicator

NCT06809725
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
SPARK Cognitive Status Indicator (software support data collected via EEG)
Diagnostic Test
Lead sponsor
Spark Neuro Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Citicoline supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting

NCT04309500
View directory record Official record
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
Personalized DAT Risk Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 14, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

NCT05661084
View directory record Official record
Conditions
Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Interventions
Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 14, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

NCT04867616
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 2:26 PM EDT